Loading...
Docoh

Cellectis (CLLS)

Participants
Arthur Stril Chief Business Officer
Andre Choulika Chief Executive Officer
Carrie Brownstein Chief Medical Officer
Bing Wang Chief Financial Officer
Gena Wang Barclays
Yigal Nochomovitz Citigroup
Kelly Shi Jeffries
Jack Allen Baird
Hartaj Singh Oppenheimer
Raju Prasad William Blair
Silvan Tuerkcan JMP Securities
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Greeting and welcome to the Cellectis First Quarter 2022 Corporate Update and Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder this conference is being recorded. I would now like to turn the conference over to your host Mr. Arthur Stril, Chief Business Officer for Cellectis. sir. ahead, go Please

Arthur Stril

welcome, financial Cellectis’ results and corporate quarter update and conference everyone, morning first to XXXX Good call.

Carrie Chief Joining with me release Wang, filed Officer; period its are our our report evening, Officer. Dr. prepared today Chief Dr. Executive Cellectis the first for remarks are interim and Chief Officer; on Dr. Andre reports results Bing the and The Brownstein, our website call Yesterday Medical our issued Financial its on XXXX. and available a ended three-months at financial and XX, press press release reporting March quarter cellectis.com. Choulika,

on we will and assumptions management's description on year XXXX forecasted. Cellectis and including XX-F reminder, product the found Form with our be our from to outlook regulatory, otherwise current SEC information over Cellectis' financial and and in December are management, by to those uncertainties on reported currently to or in Commission for Exchange can licensed risks actual filings time-to-time. the based recent that addition turn to development provided of plan. call As with partners, report the the now management statements Andre. from including these financial like subject most results the the and our statements its may and reports, and subsequently would ending XX, filed cause Securities publicly differ forward-looking makes A information manufacturing, make expectations to These available regarding are risks which I to

Andre Choulika

investigational antigen, patients myeloid be expected major development. CDXX fully or clinic. or this expressing data or forward the CAR relapsed activity on the or or our made today. everyone This cell published to strong a were single first you a providing lymphoma Cellectis’ proud and first pre-clinical this cell with for denditric leukemia for candidate manufacturing product development either on We pre-clinical integrated notable publication new against progress an into refractory cell strong plasmacytoid into with dual validation rationale to remain lines step and us therapy allogeneic tumor UCARTXXX drug with our to proud the back two discovery you, to development GMP that development. Thank clinical neoplasm product morning in-house track took Arthur. allogeneic an product and both is with in blastic demonstrated transformation This developed and to for in simultaneously. announce the pipeline our AML first candidate We We Good gene or these see being showcases proof-of-concept and Cellectis for company supports transfer from UCARTXXX a and NHL. treat data were that T-cell UCARTXXxXX preclinical UCARTXXxXX file non-Hodgkin’s back robust UCARTXXxXX, to with quarter. pre-clinical communication thank CDXX, to of BPDCN. end-to-end on evaluating data acute to UCARTXXX year. joining the We is

AML autologous complex of benefits the the therapies allogeneic T-cell of logistical with rely T clinical the While date few CAR CDXXX supports potential data preclinical on to approach evaluated strongly and BPDCN. this set challenges, in approaches and

to need. diseases patients, our that in mission specifically address We cancer medical unmet like are our to and results hard proud of AML these commitment treat very reinforced to

their on FDA to the patients be Cell B the to clinical that January, year. Drug and hold to Lymphoma with an initiating middle provide their Administration trial removed around enroll of continue a and ALLO-XXX focused cell CAR U.S. targeting which resumed TALEN with announced single in chromosomal unrelated ALLO-XXXA with of cell in now gene offer Allogene detected Pending pivotal previously patient clear of with multiple abnormality was Cellectis. T the Allogene some partnership this of Large cell refractory was X reported or investigation on T-cell. discussion for study announced to relapse Our Enrollment CDXX portion line editing or trials, ALLO-XXXA third October in clinical Food it highlight for on in is targeting that & need. In XXXX. advanced the metastatic BCMA exciting in after has treated trial myeloma determined the carcinoma. Phase patient Allogene that patient in was renal to

the Cytovia upfront of cells. Cellectis Healthcare which pluripotent for of its in April, collaboration combination Lymphocytes to in allowed once single stock with be for of developing Induced collaboration deliver partners million a to in of a therapy This special quarter, Corp., TIL the and a new an or to a genome-edited technology Acquisition payment TIL the convertible company or checkpoint and gene-editing, into also provide TALEN $XX Iovance. our next In with first to business we completion acquisition look the a Infiltrating partner TIL develop reiterate tumor cells that note Iselworth types using Iovance the solid to continuing continue The to stem multiple We common Tumor iPSC-derived is is announcements converted business company notes provides more opportunity Killer therapy, expanded opportunity. addition for Therapeutics. These generation announced Cytovia with develop technology TALEN purpose will FDA TIL our therapy. IND choice for or consideration received forward of SPAC. U.S. our proceed gene-edited upon custom significant Natural Cytovia combination TALEN-edited This that announced Cellectis’ between

in entire lymphoma made in As UCARTXXxXX few powered working our been end-to-end With during a of meaningfully year. second and operational therapy towards patient North the one supplies our I XXXX. fully sites two plan of Raleigh, the Carolina trial trial last non-Hodgkin’s company company. Cellectis becoming half in call, in stated and earnings Raleigh the in-house has Paris Cellectis UCARTXX cell in to manufacturing a this dosing in of initiate BALLI-XX gene clinical with The milestone manufactured and our

our our plan, cash current anticipate into us early XXXX. we on takes based Lastly, runway

I like the to Carrie product clinical turn to an of Carrie, preclinical Officer go give three ahead. our Dr. trials Now, overview and please over would sponsored pipeline. call Medical Chief our to Brownstein,

Carrie Brownstein

publication leukemia who Thank or the you progress initiate for relapsed that directed off CDXX to month, UCARTXXX the communications this suppression, cyclophosphamide validation cyclophosphamide overall the from and December BALLI-XX Signs the TALEN in-house lymphodepletion host lymphodepletion after and that alemtuzumab plan lymphocyte strong of year. and the Andre. alemtuzumab nature adding administration These the was level the in BALLI-XX half our UCARTXX of preliminary B-cell UCARTXX fludarabine, overview of announced dose in alemtuzumab from batches This anti-leukemic product early is of facility shelf we providing allogeneic Further, encouraging UCARTXX, patients preclinical acute patients leukemia. UCARTXXX first data XXXX, of UCARTXX. to the adversely acute at in on of released the evaluated first second currently our T-cell edited with clinic. trial. to profile. in Hematology Society in currently to treat safety American data gene addition activity annual promoted did myeloid we we sustained make not CAR our in observed. of of being with the meeting lymphoblastic enrolling manufactured At of continues refractory X fludarabine patients set Raleigh candidates shows and expansion affect the UCART-XX received of

level regimen. leukemia acute patients UCARTXXX AMELI-XX from program relapsed study evaluating T-cell Fludarabine, candidate lymphoblastic available. look We relapsed sharing UCARTCSX, with patients being or Cellectis’ this enroll edited evaluated refractory Cyclophosphamide allogeneic pre-conditioning. Alemtuzumab to TALEN becomes with is multiple in who and one pre-conditioning currently clinical Fludarabine CAR MELANI-XX continues when enrolling our and evaluating now and it product refractory forward with in will speak directed at progress to and Our patients UCARTCSX myeloma. to gene CSX I patients data Cyclophosphamide dose

UCARTXXxXX, antigen developed anticipate with product refractory risk for year an common and on CDXX killing versus UCARTXXxXX targeting. CDXX UCARTXXxXX first both to UCARTXXxXX to negative and in to excited allogeneic directed overcome cell is preclinical preclinical as persistence. lymphoma. and the of single or Lastly, disruptions potential Annual patients IND CAR that attract malignancies mechanisms the alternative has dual both meeting. relapsed Car monoclonal immune released American escape heterogeneity. filing TALEN announce to and validated at pre-conditioning demonstrated concept, to Dual with in enhance expansion we Cellectis to T-cell mediated this and the escape being resistance I'm features due candidate CAR antigen Association proof for and non-Hodgkin’s of relapses. therapy Cellectis enhance potential the targeting of These use offer to This to targets robust, and gene therapies designed of April data B-cell the host directed of disease the to antibody to graft [indiscernible] CDXX for Research established reduce of an T permit tumor CDXX, such CDXX single Cancer the to T tumor data gene prevent CDXX cell

expected the call With Chief please of investigation As financials. filed UCARTXXxXX ahead. Bing, to Officer this for that, Cellectis’ to Financial overview hand we new Bing an be an drug over for Dr. stated, would previously year. is application I on like Wang, our to go

Bing Wang

decrease to quarter first and XXX a to I operating in attributable compared XX provide in to on a expected including first XXX the as cash, position million months excluding months and impact. this attributable first million of operation the per financial million flow million months XX of excluding was brief million XXXX, compensation raise early XXXX. to a was Cellectis the you, XXXX. stock-based in like Cellectis, of net to and three and three loss equivalents, per XX of compared The million Calyxt current million in to assets, capital Cellectis, the The at plan in net difference of XXXX. reflects in in XX, months $X.XX was XXXX. of months This flows as sufficient activities, that overview XXXX were Cellectis, current a other the was XXXX, of three financials, or March to by XXXX. of XX cash was cash consolidated at or Cellectis, shareholders first capital X months This by $X.XX and restricted to million non-cash, position XXX of per loss of to Thank loss million shareholders X Cellectis, between expenditure operating, our as first compared assets, income loss Calyxt adjusted mainly and XXXX, our loss three XXXX, XX XX XX The the in would The three attributable Based of standalone financial of million of decrease cash a will three XX expenses partially projections, XX a was compared and XX, Calyxt. million December in exceeding XXX The million, X financial of financing into or the primarily XX, including exchange million leases $X.XX Calyxt, the of of position XXXX. or be first of $X.XX XXXX, net share in net shareholders for share loss the million a foreign XX, is XXXX loss restricted three operating lease cash XXXX. net March offset of first December cash used to negative and months about as XXXX in increase to Carrie. Calyxt, million net highlight revenues financial financials equivalents, share Calyxt current driven in cash, the Cellectis, first consolidated of I net compared cash gain million of and investing, used XX of cash million. fund of and $X consolidated in

in pipeline our in facilities We Raleigh. and the wholly-owned or product in are operating laser deep cash our candidates clinic developing manufacturing on spend of focused state-of-the-art our to Paris

on limited maintaining infrastructure an G&A in growth the hand, our other efficient On more should enable focus corporate expense.

Andre Choulika

editing of look second To our Thank proficiency like to we continually development order the of XXXX like Bing. lives you, the field patients effort gene technology, to enabled cell and robust our out breakthrough therapy. clinical trials gene And strongly the the lead quarter challenges in preclinical XXXX innovation pipeline we Cellectis’ deal. of are and designed pioneering based of With cancer genetic gene our and this Cellectis, into cancer leverages reiterate continuing like shift editing positioning to candidate, manufacturing to At us treat will of series with how this and development continued to and we product technology and progress which overcome with rare at has command of successful cancer, treatment call to promising transform of and this novel diseases. for forward our of beyond. candidate, in in-house that of and this capabilities upcoming scientific call, the forefront us product a believe Q&A. the paradigm about milestones that, close this would patients the clinical for to open I I excited would medical hard are the for

Operator

comes of your Our question proceed question. line from the Wang Thank with Instructions] you. [Operator Please first Barclays. Gena with

Gena Wang

taking Thank progress. congrats my the you questions and for on

allogenic yesterday, big saw release a approach graph host to Any point? try the early at saw, regarding knock CAR I'm you this So, you maybe due like approach sure what different a also picture persistence different the a start question. out or there, could versus a I with do too think you using improve first, the [indiscernible] better thoughts [indiscernible] pretty we or would just the you T approach, think it's approach. think and have be slightly you do

Arthur Stril

for Hi, Gena. the think for one Andre. And so is much probably Thank you this one I question.

Andre Choulika

the it's appreciated. Thank for you, Thank also question Gena you

ways much different this. Of of tackle been to graft of series course, has type the as type series host as versus versus do like host graft been well of this of different to and very the we've approaches advancing investigated

has Of our used first and as CDXX pre-treatment resist TCRαβ used Cellectis, with CDXX the [GBHD] which that Allogene platform the XXXX been always but one course, partner is knockout the for and plus company in TCRαβ been the has also knockout, since in [indiscernible]. [ph] with today to Alemtuzumab,

can or/and and self-lymphodepleting CAR patient lot treat that a we patient products myeloma UCARTCSX immune different Therefore, see this at graft in can does activity the the does which we provoke of prevent knock-out [indiscernible] get the clear self this the and where has that to last pay We've Of multiple in CSX tumor killing, is a self itself year and has course, of this the to and the ASGCT for and type weeks into shown CSX month of is and knock-out and category, one not CSX present CSX of during graft. period. several cells. the

soon targets a So, but that ASGCT probably developing think depleting the that's I self this has T and procedure and very many grafting presented property. by for scientists at for interesting be approaches so been years next communicate to CAR of as CSX some it's the using that going and there our like that GCT, of to such be Cellectis CSX, have we'll will this. be are not very on for interesting all going And the one

space. do are of often And not different bound several are in this one we that to that do there it, course, – So, And ways. of but way very approaches of to series course, every that can things can copied. be we

Gena Wang

you Okay. much. very Thank

Operator

Thank you.

your Citigroup. proceed next of the Our from comes Yigal question with question. line Please Nochomovitz with

Yigal Nochomovitz

Andre, taking on Hi, Bing and question. had and the just XXxXX. team. I two Thanks

expecting be since you. does the capacity with have still in So two expand regard the capacity? the be other manufacturing products? to away peak to same you that you on you to secondly, Raleigh lower antigens a range you're or to as capacity in will what with your Thank this get can current dose first, expect dose going what And the able the one-cell XXxXX, with product, mean be And is do then there? manufacturing to just down you for manufacturing obviously in

Arthur Stril

for so They clinical I manufacturing over one Hi, the you Yigal. to both it will take Thank hand then the questions. first great. are much question. on and for Carrie

entirety from to So, to of extremely on manufacture both Raleigh we're manufacturing, manufacturing us now really A the running, excited Paris product are Z. and allows mean, which and up our I our that

DNA; is Raleigh. allogeneic in the plasmid which T the devices, electroporation buffers, CAR delivered product way our including mRNA, viral vectors with to candidate So, all proprietary

company moving big ability our a forward clinical geared be to commercial truly the milestone for trials Raleigh CAR allogeneic T of supporting supply. for the that's up we definitely entirety then to be designed So the and and

definitely And XXxXX? hand the on that's question clinical the over it to plan. So will for I Carrie

Carrie Brownstein

Hi, Nice Yigal. to from hear you.

So, good yes, really that's a question the about dosing.

dual allogeneic cell with couple tumor think [indiscernible] to antigen the and CAR XXxXX as antigen things. the designed well potentially I promote between from targeting the really as is on One is, T the a help dual relapse. escape enhance the for expansion, of

antigens reasons like land. it's we'll on helpful through the and going why would that's for dose two different the CAR clinic. have dose on why how see antigens we there's in we upfront think our hard ourselves said, go and two determine escalation else be I anything That that's to to So, for where translate to our trial

Yigal Nochomovitz

Thanks. Understood.

Operator

you. Thank

Our next the question with your line from of Kelly proceed with question. Please Jefferies. Shi comes

Kelly Shi

first for question in-house is, are question far share far Thanks. could anticipated is how in transfer questions. payments taking the And progress you Thank so over My on Cellectis? the you UCARTXXxXX, the to tech next and second my are the manufacturing what XX and months process products the validation? milestone in you

Arthur Stril

so Kelly. you Thank great. much, Yes,

of so manufactured reminder, at manufactured of in-house. manufactured replacing has on this first the announced that UCARTXXxXX Raleigh, will by at UCARTXXxXX question, UCARTXXxXX CMO So, version the year, been just our way current be we with we've

this filing order the product end using has year. release and FDA the the by the then clinic So, in to be of at We're be in of the the finalizing second happened we'll manufacturing at with Raleigh. half year data

a that this you and obviously half with definitely year. the going in second that's of share So, milestone great we'll to be

the milestone regarding payments. Now,

of ALLO-XXX. is of expecting trial we're milestone I think entry the main the significant pivotal year this that

allogeneic So, T the we all. candidate licensed anti-CDXX CAR to product

has to definitely a Allogene And pivotal other in go payment that we'll ALLO-XXXA this sorry, enter trigger mid guided please Cellectis. year, ahead. they have So, will with will trial milestone which milestones…

Kelly Shi

Sorry. Go ahead.

Arthur Stril

was Cytovia. coming with I other are to going partnerships will from say, Allogene also that and milestones have Allogene, Iovance, we

Kelly Shi

much. very you Thank

Operator

you. Thank

next with comes question proceed of Our from Richter Sachs. line Salveen Please your question. the Goldman with

Unidentified Analyst

Hi, Salveen. on is This Matt thanks. for

likely When could know show you when the for data? data was the of that pivotal also quick much. guide those Phase positive, there I And likely? you didn't about path, would potentially question any there us anything on could you indications And specific Thank there but you XXX. partnerships, assume CAR regard with excited separately into most in to remind in a very registrational the release, we then a the move thinking if do I X are or market study? press the be on Just wondering consider when to we anything are XXX, you unfit, fit then assets versus AML? And about? opportunity you're should are on then is

Arthur Stril

Great.

take end. So, questions the on I and clinical to partnerships question over then XXX at will hand Carrie the the I will

Carrie Brownstein

much thanks so for that. Hi,

excited still the extremely we're program. So, about UCARTXXX

as or That through relapsed are fragile questions your some well refractory and and AML extremely excited to difficulties on moving of extremely difficult to given AML, based particularly remain You forward. treat. extremely aware, the program we know even disease move about the patients just it are AML. you is said, of challenging The it's an

investigators. can what to going engaged We moving data, say right to I in program right the yet extremely we’ve but we're, path and that through clinical the we're program We're that guided ensure plan the to we're have when as very forward. the we excited forward, and haven't development moving is share

Arthur Stril

Yes.

mean, the is, what's And pipeline current shots I several so interesting goal. think we partnership, have I the very on on with

is the malignancies risk – as have four will in shorts goal year hematological profiles. soon different XXxXX as clinic in different with very you this very got with We

definitely I Cellectis. and definitely our all think altogether for I ability the these So, is asset a products interesting these pipeline different to having think assets are defining have in

Operator

Thank you.

of comes Jack Baird. with Allen Please question the line your proceed from next with Our question.

Jack Allen

much. some and with of sequence, CAR progress you the to right IP, now care and view you therapies? that unique on your the on their you Congrats as and but position hoping data unique taking from believe modalities, thank the just gene-editing plan have it's creating They you that allogenic TCR regard how with competitor one interesting was I the on team. to IP could a with IP a a editing I relates knockout it much a so yesterday cell leverage have use questions. I more gene to CDXX Hi aspect saw we touch allogenic so targeted little for just of variety bit T. Thanks

Arthur Stril

Excellent for question. Andre hand over I'll Jack. this one. Thanks, to it

Andre Choulika

type and is all the of going from very to Well, around. out and or drugs innovation we've been like or long what this gene have Well, genes therapy, but [indiscernible] such very of now course always for IP company has patents have is in [ph], [marketplaces] space had with are the been regimen TALEN, is of replacement – knocking based as the lymphodepletion before cells also of different a our and engrafting through, for we example, beta-X certain been IP IP such Cellectis umbrella doing questions like by cell the now a position nice gene-editing of been a we've enhance the lot in from changing that HLA-E IP etcetera in as commercialized and period for of to the commercialized. interesting and we've been covering CDXX, going of been space the package these therapies covering engraftments that And microglobulin for none series patterns also of that also using [Crisper] [ph]. time

company an of I that the IP the would once a the interesting be market And BLA be very so, first to position that today holds that the amount partner and we the start competition will the the will then for then development product file soon. hitting think all is competition And potentially to IP. first in that ALLO-XXXA, BLA from become one the still be would large will is our situation other one a to hope asset change file the and the clinical totally Allogene

this something in do. we're of referring detail, the course to answers that commenting more Now hope I that a question. all will be

Jack Allen

great Thank so much. you contact. [Indiscernible]

Operator

Thank you.

Our Oppenheimer. with the with comes Singh your of Please line from next question. Hartaj proceed question

Hartaj Singh

for and you two Thank Great. the the updates. all questions nice really

on could look is like? project [ph] to IND Will and in there the your it expansion. on. number file Number sure on X two protocol you getting, some expansion? the Phase with finalized be idea CDXX you getting refractory CDXX, [XXxXX] you're a is all dose question what just dose how Can going dose escalation do give sort CDXX, financial dose I'm patients, the area question. close into of expansion, then could maybe envision you're commerce dose for to us That's first it one. The happening that escalation the going that

from you about of So, are through months that not envelope to it to of of milestone you. runway. guidance assumption to we're That's that looks kind in. and some essentially for XX Can coming maybe make going $XX around partners sort that million you rough of XX your coming give there, that's of if next pretty an we a get XXXX back months. looking over do chunk the I change to, good color have but payments, like kind us just million $XX math, the Thank potentially runway means in cash to just

Arthur Stril

Hartaj, Hi, the questions. so thanks and for much

and it Bing to the for Carey I'll definitely one. is over The second hand first one for

Carrie Brownstein

Yes. hear Good are Hartaj. Hi, from you? you. How to

UCARTXXxXX the excited So, about program. we're incredibly

a and well program concept, as therapy, not of but our what think CART is are NHL aware, is autologous where about a in only high you medical As allogenic remains unmet space also need has proof for been cell well. tremendous for great I there

you Phase haven't our look it, then, there. we but be asking. given you going to disclosed know, are see already like. think a it's, your it'll will you look interesting through X it what when that's very it'll concept Suffice design of is clinicaltrials.gov, say, open this we we move know, on You in to – for the like it'll good to place Thank I proof and quickly, be

Hartaj Singh

Carrie. Great. Thanks

Carrie Brownstein

Sure.

Bing Wang

on payment. we this are cash comfortable guidance And have milestone based And we on all we for is can and our on Hart, right, that you're that those question question, now. And is now. on answer provided position right your assumptions cash with some already

Hartaj Singh

Great. Alright. Thank you Bing.

Operator

you. Thank

Our line of Raju with William your next question with Blair. comes Prasad question. from proceed the Please

Raju Prasad

question. for taking Thanks the

wondering, taking for, and extend Just as expectations rejection see you curious still approach kind mean, know could question you know has into the durability? antigen clinic, have to is it seeing of question XX specificity we're you reason after thus it far? XX you're the the the think why of that And was some in been XXxXX know, the kind is clinic seen here that this and I that. I I in candidates we've kind we I of of Allo a think then big

Arthur Stril

question. interesting Raju. Very Hi,

place. Carrie best is think the I probably

Carrie Brownstein

Sure.

both having of and have the those that dual improved express expansion, improved killing for may more contact I well antigen, you the cells I express who as antigen had I kill [indiscernible] XX, that XX have approach as the both. only about potential expressing are think as increased is tumor or lots with mentioned are actually to think or only cells patients who that earlier, etcetera, those opportunity

it really mechanism So, a a killing than provides antigen. much broader with single

re-dose, In We durability durability. space, there's terms in We is of expansion of persistence long-term have know that want not auto the to in an ourselves persistence the easy longer-term because more from to AOL, that's space, mainly which do need least of ability but of the persistence. engraftment necessarily durability persistence, appropriate long-term that for And at don't well enough to in the facilitate as data looking data with not think shown as certain looking is I order for only again, a than are killing. the really killing, our that the the responses. we and a we're allogenic necessarily amount I and

the I because continue knockout, using to which and to CDXX for want really think persistence B out really think period of as time. know many to Cell it as a of of is So, needed, you space, dial-out not Alemtuzumab again, we're going have allows that approach, antigens persistence approach we outside kind that terrific the that the there's with our is there significant you dial-in would well a

So, that our we we able do be we're we really going to believe strategy. see And need current in strongly persistence durable responses. the think

Raju Prasad

Great NK this to AML wanted year. announced was some just thanks. some get the And on comments earlier that then of data I cell,

some their the that negativity in Just that approach? the thoughts your when CRs, something of on should how is of showing that kind up, anticipate a T-cell kind with you that Thanks. NK readout on XXX MRD curious cells sets XXX is think we approach cell

Arthur Stril

Yeah. one is you as Carrie, this well. for

Carrie Brownstein

was and the I improve call, outcome and horrible as see aggressive data. AML is to I AML that, is thing. in [indiscernible] Sure. a the as patients of to I many Again, disease with excited go said on shots the earlier incredibly an positive the extremely such lives think and

were that work happy I well actually shows the allogeneic programs see to can we really for well approach And So, of that our bodes data. context as in think it AML. and

in looking the as we're and said, forward sharing we when strongly I to very program So, data believe and have still, engaged we investigators. are available have it

the have it. we when think we share will data I So, share,

Raju Prasad

Carrie. Thanks

Carrie Brownstein

Sure.

Operator

Thank you.

with Our next with the Please line Tuerkcan of proceed from JMP question. Securities. Silvan comes question your

Silvan Tuerkcan

Thank quick for questions. and taking you. two that have I on congrats Thanks my question progress.

out lymphodepletion a more Caribou, first about The use [indiscernible] yesterday. regimen. that data the they The came enhanced one,

ongoing and you for here? needle of may it's and as well they to the that leverage are selection? and seeing that my UCARTXXxXX can trials the and trials PDX KO be patient Thank expansion something that the lymphodepletion you kind not maybe second question only the what you. at directly was is may around dosing your selection, to then looking the be of from inform kind Allogene from And responsible thread learnings So, that that greater also

Arthur Stril

Hi are over Carrie. two Silvan. to These and questions it I'll great pass

Carrie Brownstein

Yes. Silvan. Thanks. much Thanks so

to doses doses. have think higher I on that right? I [flu] the the the yeah, lymphodepletion, their dependent you interesting. in disease careful, addition is particularly enhanced It's that But do of think very be to data So, mean, treating you're I and [ph], super

of are desecrated little marrow been patients They're a context by more the chemotherapy. in completely healthier. hasn't example, sturdy. less for rounds multiple those lymphoma, They're So fragile. of Their

doses maybe okay they and doses precision and toxicity. saw from effects] And AOL significant [ph] example for actually higher was lead think so, they saw things. where I'm much and not infection you to in and to toxicity and of higher the, gave among sure other data a leading was [indiscernible] it issues NHL of and [great it those side patients the [indiscernible] higher from I

approach, giving more it but thread, very fine with to not sorry the to which knockout, us lymphodepletion an gives CDXX why, selective our we approach you depletion, cells, a it's drug is understand know a to other opposed is as we and someone's well. Alemtuzumab also NK chemo, and know with selective It has again, that T-cells, with because marrow. So, profile that and And out knocking lymphocytes well. flu, the needle enhancement but

published [NTCN] We by strong of you terms [ph]. very know are been guidelines in have for which management – toxicity infections,

of been may very that's comfortable much speak us and and lymphodepletion something we're with tweaking, that to have populations. for around to look and is what and more manageable for a long allows specific patient manageable like So so this time,

sold how on progresses goes we're doing and their we'll time as data So, their on. data, see how what we're

Operator

session. you. comments. Ladies the concludes that for floor to any Choulika and Mr. gentlemen, our turn I'll back Thank final question-and-answer

Andre Choulika

has ongoing trials everyone for different methods is very approaches a for in using CAR for leading this with I your Allogene, our [ph], and expansion, cell us a fantastic Servier, into being period of space of very know etcetera, been but also type Cellectis Cytovia where much we're are interestingly into positioned you a we're special lymphodepletion, but time. also [AAV’s] partners, ongoing, and There a very space. lot therapy. Iovance that gene lot see different different that we Thank for of

Now, in into where make phases approach, two when we at and that myeloma. data have new asset, are we from probably some XXxXX, conference, up differentiated; on for providing which four that XX, excited which comes end from another CSX it we're up about are thing see XXX, doesn't finally time allogenic CDXX registration getting our out is with the data are with is a doing. come also multiple get products to a selected us, etcetera, we're a like labs going long with new excited lymphoma, what and differentiated our we and by will that first come that non-Hodgkin’s is new of which been being partners the with differentiated; the period And in

to cell Thank this please be the contribute watch gene time, is So, to company and a very good in very your Cellectis interesting going is and I and this a bit and here much next is to to what's you day. for for month the space therapy have going in whole space. think happen

Operator

concludes you. Thank today's This conference.

lines disconnect at Thank may your participation. for You time. this your you